Skip to content

Apoe Impact Study on Brain Structure and Function, in a Population 45 to 75 Years Old

Apoe Impact Study on Brain Structure and Function, in a Population 45 to 75 Years Old

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02198586
Enrollment
575
Registered
2014-07-23
Start date
2014-04-30
Completion date
2015-09-30
Last updated
2017-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Keywords

Alzheimer's, MRI, APOE

Brief summary

The purpose of this study is to investigate the influence of the APOE genotype on brain morphology, function and metabolism, related to other factors such as cognitive reserve, cognition and episodic memory, in subjects at greater risk of developing AD.

Detailed description

The purpose of this study is to investigate the influence of age and the APOE genotype on brain morphology and function, in 700 cognitively healthy individuals, 45 to 75 years old, recruited from an ongoing longitudinal cognition study exploring memory and executive functions (ClinicalTrials.gov ID: NCT01835717). All subjects have been APOE genotyped and underwent a clinical and cognitive assessment. Within this study, the subjects will be submitted to an MRI scanning protocol including morphological and resting state acquisitions. An identical follow-up MRI session will be performed in 2 years' time. The analyses will be focused on detecting the effect of the APOE allelic variants on the change rate of the neuroimaging variables as well as its interaction with aging.

Interventions

None listed

Sponsors

Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
45 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Participant included in the study ClinicalTrials.gov ID: NCT01835717 * APOE genotype obtained before MRI acquisition * Be willing to perform an MRI and agree to a 2 years longitudinal follow up * Sign informed consent

Exclusion criteria

* Contraindication to MRI scanning: claustrophobia, pacemaker, history of ocular cerclage, heart valves, aneurysm clips and carrying any metal prosthesis incompatible with MRI. * Incidental MRI findings that result in the images not being included in the study.

Design outcomes

Primary

MeasureTime frame
Hippocampal atrophy2 years

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026